Intent-to-treat analysis and preventive vaccine efficacy

Vaccine

Volumn 19, Issue 2-3, 2000, Pages 319-326

  Horne, A Dale ^a   Lachenbruch, Peter A ^a   Goldenthal, Karen L ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Clinical trials; Intent to treat; Per protocol

Indexed keywords

VACCINE;

ARTICLE; DATA ANALYSIS; DRUG EFFICACY; IMMUNE RESPONSE; IMMUNIZATION; MATHEMATICAL MODEL; PREVENTIVE MEDICINE; PRIORITY JOURNAL; VACCINATION;

EID: 0034666744     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00152-3     Document Type: Article

References (45)

1. Armitage P. Exclusions, losses to follow-up, and withdrawals in clinical trials. Shapiro S., Louis T.A. Clinical trials: issues and approaches. 1983;Dekker, New York.
2. Canner P.L. Monitoring clinical trial data for evidence of adverse or beneficial treatment effects. INSERM. 76:1977;131-149.
3. Fisher L.D., Dixon D.O., Herson J., Frankowski R.K., Hearron M.S., Peace K.E. Intention to treat in clinical trials. Peace K.E. Statistical issues in drug research and development. 1990;Dekker, New York.
4. Friedman L.M., Furberg C.D., DeMets D.L. Fundamentals of clinical trials. 3rd ed. 1998;Springer, New York.
5. Gail M.H. Eligibility exclusions, losses to follow-up, removal of randomized patients, and uncounted events in cancer clinical trials. Cancer Treat. Rep. 69:1985;1107-1113.
6. Gent M., Sackett D.L. The qualification and disqualification of patients and events in long-term cardiovascular clinical trials. Thrombos. Haemostas. 41:1979;123-134.
7. Gillings D., Koch G.G. The application of the principle of intention-to-treat to the analysis of clinical trials. Drug Inform. J. 25:1991;411-424.
8. Lee Y.J., Ellenberg J.H., Hirtz D.G., Nelson K.B. Analysis of clinical trials by treatment actually received: is it really an option? Stat. Med. 10:1991;1595-1605.
9. Lewis J.A., Machin D. Intention to treat - who should use ITT? Br. J. Cancer. 68:1993;647-650.
10. May G.S., DeMets D.L., Friedman L.M., Furberg C., Passamani E. The randomized clinical trial: bias in analysis. Circulation. 64:1981;669-673.
11. Meier P. Statistical analysis of clinical trials. Shapiro S.H., Louis T.A. Clinical trials. 1983;Dekker, New York.
12. Meinert C.L. Clinical trials: design, conduct, and analysis. 1986;Oxford University Press, New York.
13. Peto R., Pike M.C., Armitage P., et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br. J. Cancer. 34:1976;585-612.
14. Peto R., Pike M.C., Armitage P., et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br. J. Cancer. 35:1977;1-39.
15. Pocock S.J. Clinical trials: a practical approach. 1983;Wiley, New York.
16. Sackett D.L., Gent M. Controversy in counting and attributing events in clinical trials. New Engl. J. Med. 301:1979;1410-1412.
17. Clemens J.D., Naficy A., Rao M.R. Long-term evaluation of vaccine protection: methodological issues for phase 3 trials and phase 4 studies. Levine M.M., Woodrow G.C., Kaper J.B., Cobon G.S. New generation vaccines. 2nd ed. 1997;Dekker, New York.
18. Peduzzi P., Donta S., Iwane M. A review of the design of vaccine efficacy trials and a proposal for the design of the VA cooperative study of active immunotherapy of HIV infection. Controlled Clin. Trials. 18:1997;397-419.
19. Tsoukas C.M., Raboud J., Bernard N.F., et al. Active immunization of patients with HIV infection: a study of the effect of VaxSyn, a recombinant HIV envelope subunit vaccine, on progression of immunodeficiency. AIDS Res. Hum. Retroviruses. 14:1998;483-490.
20. Eron J.J. Jr, Ashby M.A., Giordano M.F., et al. Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection. Lancet. 348:1996;1547-1551.
21. Straus S.E., Wald A., Kost R.G., et al. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. J. Infect. Dis. 176:1997;1129-1134.
22. Straus S.E., Corey L., Burke R.L., et al. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet. 343:1994;1460-1463.
23. Roland M., Torgerson D.J. Understanding controlled trials: what are pragmatic trials? B.M.J. 316:1998;285.
24. Boudes P. Drug compliance in therapeutic trials: a review. Controlled Clin. Trials. 19:1998;257-268.
25. Greco D., Salmaso S., Mastrantonio P., et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N. Engl. J. Med. 334:1996;341-348.
26. Gustafsson L., Hallander H.O., Olin P., Reizenstein E., Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N. Engl. J. Med. 334:1996;349-355.
27. Taranger J., Trollfors B., Lagergard T. Clinical trials of a monocomponent pertussis toxoid vaccine (NICHD Ptxd) - a technical report. 1995;Goteborg Pertussis Vaccine Study, Goteborg University, Sweden.
28. Trollfors B., Taranger J., Lagergard T., et al. A placebo-controlled trial of a pertussis-toxoid vaccine. N. Engl. J. Med. 333:1995;1045-1050.
29. Santosham M., Wolff M., Reid R., et al. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. N. Engl. J. Med. 324:1991;1767-1772.
30. Werzberger A., Mensch B., Kuter B., et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N. Engl. J. Med. 327:1992;453-457.
31. Francis D.P., Hadler S.C., Thompson S.E., et al. The prevention of hepatitis B with vaccine. Report of the Centers for Disease Control multi-center efficacy trial among homosexual men. Ann. Intern. Med. 97:1982;362-366.
32. US Food Drug Administration Vaccines and Related Biological Products Advisory Committee Meeting, Bethesda, Maryland, 26 May, 1998.
33. Steere A.C., Sikand V.K., Meurice F., et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group. N. Engl. J. Med. 339:1998;209-215.
34. Black S., Shinefield H., Ray P., et al. Efficacy of heptavalent conjugate pneumococcal vaccine (Wyeth Lederle) in 37,000 infants and children: results of the Northern California Kaiser Permanente efficacy trial. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstr. LB-9. San Diego. 24-27 September, 1998. 1998.
35. US Food Drug Administration Vaccines and Related Biological Products Advisory Committee Meeting, 5 November, 1999.
36. Eskola J., Kilpi T. Efficacy of a heptavalent pneumococcal conjugate vaccine (PncCRM) against serotype-specific, culture-confirmed pneumococcal acute otitis media (AOM) in infants and children. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstr. San Francisco. 25-29 September, 1999. 1999.
37. Monto A.S. Francis field trial of inactivated poliomyelitis vaccine: background and lessons for today. Epidemiol. Rev. 21:1999;7-23.
38. Klugman K.P., Gilbertson I.T., Koornhof H.J., et al. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet. 2:1987;1165-1169.
39. Feinstone S.M., Gust I.D. Hepatitis A virus. Mandell G.L., Bennett J.E., Dolin R. Principles and practice of infectious diseases. 2000;Churchill Livingstone, Philadelphia.
40. Black S.B., Shinefield H.R., Fireman B., Hiatt R., Polen M., Vittinghoff E. Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. Pediatr. Infect. Dis. J. 10:1991;97-104.
41. Vaccine Safety Committee. Haemophilus influenzae type b vaccines. Stratton K.R., Howe C.J., Johnston R.B. Jr. Adverse events associated with childhood vaccines: evidence bearing on causality. 1994;National Academy Press, Washington, DC.
42. Cuzick J., Edwards R., Segnan N. Adjusting for non-compliance and contamination in randomized clinical trials. Stat. Med. 16:1997;1017-1029.
43. International Conference on Harmonisation. Statistical Principles for Clinical Trials. Efficacy Guidelines. Federal Reg 1998;63:49,583-49,598 ( www.fda.gov/cber/guidelines.htm ).
44. Jones B., Jarvis P., Lewis J.A., Ebbutt A.F. Trials to assess equivalence: the importance of rigorous methods. BMJ. 313:1996;36-39.
45. Fedson D.S. Measuring protection: efficacy versus effectiveness. Dev. Biol. Stand. 95:1998;195-201.